Wirelessly controlled, bioresorbable drug delivery device with active valves that exploit electrochemically triggered crevice corrosion

See allHide authors and affiliations

Science Advances  28 Aug 2020:
Vol. 6, no. 35, eabb1093
DOI: 10.1126/sciadv.abb1093


Implantable drug release platforms that offer wirelessly programmable control over pharmacokinetics have potential in advanced treatment protocols for hormone imbalances, malignant cancers, diabetic conditions, and others. We present a system with this type of functionality in which the constituent materials undergo complete bioresorption to eliminate device load from the patient after completing the final stage of the release process. Here, bioresorbable polyanhydride reservoirs store drugs in defined reservoirs without leakage until wirelessly triggered valve structures open to allow release. These valves operate through an electrochemical mechanism of geometrically accelerated corrosion induced by passage of electrical current from a wireless, bioresorbable power-harvesting unit. Evaluations in cell cultures demonstrate the efficacy of this technology for the treatment of cancerous tissues by release of the drug doxorubicin. Complete in vivo studies of platforms with multiple, independently controlled release events in live-animal models illustrate capabilities for control of blood glucose levels by timed delivery of insulin.


Implantable devices for drug delivery offer powerful capabilities in localized and controlled pharmacological treatments, where structural designs and/or material properties support the necessary functionality. Most of these platforms rely on passive drug diffusion from porous scaffolds or on release from soft polymer matrices that biodegrade over time (14). These devices operate on the basis of diffusion-controlled leakage of drug molecules, with rates that depend on the state of the system as it interacts with the surrounding biology. Although technologies with electronically programmable valves built into reservoirs and fluidic channels enable much greater versatility in the controlled drug release kinetics (57), secondary surgical procedures to extract the implanted hardware after completion of the delivery function are required. To overcome these key disadvantages, drug delivery platforms should ideally incorporate (i) active systems with wireless control, (ii) mechanically stable reservoir structures with complete sealing for zero leakage of drugs in the off state and compatibility with any drug chemistry, and (iii) fully bioresorbable construction to eliminate the need for secondary surgical removal processes after treatment.

Recent reports describe active classes of bioresorbable electronic systems that store drugs in porous polymer molecular matrices or chemically conjugated polymer structures, where wirelessly delivered thermal stimuli trigger the release processes (810). Tao et al. (8) describe thermally accelerated drug release devices that use a silk-based structure, but with rapid rates of degradation and disintegration, often within timescales of minutes or hours. Lee et al. (9) report electronically programmable devices based on temperature-sensitive lipid-based structures. A disadvantage is that the lipid can collapse due to its weak molecular bonding, leading to unwanted leakage of drugs. Another approach (10) uses a wireless, thermal actuation scheme to release physically trapped and covalently conjugated drug molecules from an oxidized starch–based structure. In particular, hydrophilic drug molecules remain within the materials structure, and heating (~42°C) accelerates diffusive release. Although these hyperthermic platforms (812) offer advantages over many other options, limitations follow from their sensitivity to uncontrolled variations in temperature over a narrow operating range, mechanical perturbations, and/or swelling of the polymer matrices during or after implantation. Moreover, these platforms are not drug release vehicles in the engineering sense of reservoirs, valves, channels, and other fluid handling systems. As a result, the payloads and release kinetics are constrained by the degradable matrix and the nature of the molecular interactions that are responsible for binding.

Here, we introduce an approach that allows deterministic control over the delivery process in the form of a completely bioresorbable electronic system that combines biocompatible wireless power-harvesting function with electrochemically degradable valves and a system of reservoirs constructed from a bioresorbable polymer. The result provides for programmable control over drug release in a platform that disappears completely and naturally in the body without residue. Specifically, wirelessly delivered electrical current initiated by proximity to a transmission coil leads to electrochemically accelerated dissolution of a metal gate structure that seals drug-containing reservoirs constructed in a bioresorbable polyanhydride. Unlike hyperthermic actuation (812), this crevice corrosion phenomenon for opening of the gate enables fast and energy-efficient drug release. Exploiting this scheme using metal gates with various shapes and sizes allows the delivery of effective doses to target tissues with desired kinetics. As a result, this technology enables in situ, on-demand release of single or multiple classes of drugs from a collection of independently controlled reservoirs, with precise control of the release timing and near-zero parasitic leakage over extended periods of time. Systematic in vivo and in vitro studies demonstrate the underlying principles and all of the relevant features of operation.


Structure and operation of bioresorbable, wireless drug delivery device

Figure 1A highlights the design aspects and key materials for a simple system of this type, consisting of a polymer reservoir, a wireless power harvester, and a metal gate valve. Polybutanedithiol 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione penteonic anhydride (PBTPA), a bioresorbable polyanhydride (13), serves as a substrate and a containment vessel for an aqueous drug of interest. Synthesis of the PBTPA relies on thiol-ene click reactions of three compounds initiated by exposure to ultraviolet (UV) light: 4-pentenoic anhydride (4PA), 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (TTT), and 1,4-butanedithiol. The UV curing process facilitates the use of molding and/or machining techniques, to yield platforms of this type with a range of sizes and shapes, as indicated in fig. S1. The simple example shown here involves a single reservoir, with a pair of magnesium (Mg) electrodes assembled with the PBTPA housing. The wireless power harvester relies on magnetic inductive coupling to an external transmission coil to produce an electrical bias between the Mg electrodes, where one serves as an anode (referred to as the gate, which functions as the valve to an underlying reservoir) and the other as the cathode. This harvesting unit consists of a radio frequency (RF) coil of Mg, an RF diode constructed using a silicon nanomembrane (Si NM), and a parallel-plate capacitor in a multilayer stack of Mg/SiO2/Mg, as shown in Fig. 1A(i). The resonance frequency is ~5 MHz, as shown in Fig. 1B, with scattering parameters, quality factor, and inductance values consistent with computational modeling (note S1). Magnetic coupling at this frequency involves negligible parasitic absorption by biological tissues (14, 15). A relatively high Q ~ 15 (Fig. 1C) allows for long operating distances (~5 cm). A transmission coil (80-mm diameter, 3 turns, and winding with 1.6-mm diameter copper wire) added to the simulation model yields a relationship between the power transfer efficiency and operating distance, as shown in Fig. 1D (detailed information is in note S1).

Fig. 1 Wirelessly programmable, bioresorbable drug delivery system.

(A) Illustration and images of an implantable and wirelessly controlled bioresorbable drug delivery system with an electrical triggering unit that includes a radio frequency (RF) power harvester with a Mg coil, a silicon nanomembrane (Si NM) diode, and a Mg/SiO2/Mg capacitor, [A(i)]. (B) RF behavior (scattering parameter, S11) of the harvester (black, experiment; blue, simulation). The resonance frequency is ~5 MHz, selected to allow magnetic coupling with little parasitic absorption by biological tissues. (C) Simulated inductance (black) and Q factor (red) of a single coil with a diameter of 16 mm. (D) Transmitting power as a function of the distance between the transmitting coil and the device (black, experiments; red, simulation). Experimental data are means ± SD; n = 3. (E) Images of wirelessly controlled release of a blue dye in water during immersion in phosphate-buffered solution (PBS; pH 7.4). (F) Accelerated dissolution of an entire system due to immersion in PBS (pH 7.4) at an elevated temperature, 85°C. Photo credit: Jahyun Koo, Korea University.

The optimized power harvester generates an overpotential (bias), which leads to accelerated electrochemical etching with geometrical effects induced by the PBTPA housing. First, a bias develops between the anode gate and the cathode upon activation of an RF transmission coil placed in proximity to the device (14). This bias results in irreversible Faradaic reactions enabled by surrounding biofluids (15), according to the following anodic reaction: (Mg → Mg2+ + 2e) (16). This reaction opens the gate and causes the release of drug from the underlying reservoir. Figure 1E demonstrates wirelessly controlled release of water (4 ml, dyed blue) from a reservoir of a device immersed in a bath of phosphate-buffered saline (PBS; Sigma-Aldrich, USA) due to opening of the gate by electrochemical etching induced by passage of RF power (~12 mW into the receiver coil; 8 W into the transmission coil) through a transmission coil located at a distance of 2 cm outside of the bath. This process induces no notable heating (fig. S2). In this manner, the system supports the wirelessly controlled release of drugs, on-demand and with access to various amounts of drug solution (micro- to milliliter), as key advantages compared to conventional systemic delivery.

Dissolution studies of whole drug delivery system

A key defining characteristic of the system is that all of its constituent parts undergo complete dissolution into biocompatible end-products (17). Figure 1F illustrates the processes associated with accelerated dissolution of the entire system in a bath of PBS (pH 7.4) at 85°C for more than 4 weeks, including the PBTPA reservoir (100 μm), the Mg (50 μm, ~100 μg) RF coil encapsulated by PBTPA (20 μm), Si NM (320 nm) RF diode, and Mg/SiO2/Mg (30 μm/100 nm/30 μm) capacitor (fig. S3). The rate of dissolution of PBTPA can be adjusted through control of the molar ratios of 4PA, TTT, and 1,4-butanedithiol, which for cases explored here are 1:4:7 (referred to as PBTPA 1:4:7) and 1:1:2.5 (referred to as PBTPA 1:1:2.5) (13). The results of Fig. 1F use the latter formulation. Since the 4PA contains hydrophilic and degradable bonds and 1,4-butanedithiol provides hydrophobic chains, a high ratio of 1,4-butanedithiol in PBTPA (1:4:7) extends the time for dissolution. The corresponding time at body temperature can be estimated from results obtained at elevated temperatures and associated Arrhenius scaling relationships to approximate the temperature dependence (18)kPBTPA=k0exp(EA/RT)where k0 is the preexponential factor, EA is the activation energy, R is the universal gas constant (=8.314 J∙K−1 mol−1), and T is the absolute temperature. Measured rates of dissolution of the PBTPA (1:1:2.5) at different temperatures (0.5, 6.7, and 16.3 mg/day at 23°, 60°, and 85°C, respectively), yield values of k0 and EA as 3.29 × 108 and 51,500 J∙mol−1, respectively (fig. S4). As a result, the PBTPA reservoir (1:1:2.5, 450 mg, 100 μm thick) has a projected lifetime of ~660 days at 37°C in PBS (pH 7.4). The other individual components of the system dissolve more quickly than the reservoir, ~50 days for the Mg (50 μm) coils (19), ~100 days for the Si NM (320 nm) diode (20), ~60 days for the Mg/SiO2/Mg (30 μm/100 nm/30 μm) capacitor (21), and ~30 days for the Mg (30 μm) electrodes. The time for dissolution of the system can be reduced by decreasing the thickness of the PBTPA or by adjusting the molar ratios of the reactant chemicals, to values in the range of a few hundred days.

Opening mechanism by electrochemically triggered crevice corrosion

A critically important aspect of the release mechanism is that the confined geometry at the interface between the gate and PBTPA housing leads to accelerated rates of electrochemical etching, sometimes referred to as crevice corrosion (16, 22, 23), as shown in Fig. 2A. Figure 2B presents an illustration and a set of images of the system and the location of the gate defined by the housing. The insets of Fig. 2B show optical microscope (OM; left) and scanning electron microscope (SEM; right) images of the results of electrochemical etching with a bias of 1 V for 180 s. Images of the backside of the gate shown in Fig. 2C and fig. S5 illustrate that the highest etching rates occur at the vertices, followed by the edges. Electrochemical impedance spectroscopy (EIS) measurements performed at regular time points during the etching process yield insights into the gate morphology and the gate-electrolyte interface. Figure S6A shows a schematic illustration of the interfaces between the gate and biofluid and of a Randles’ equivalent circuit (24). Here, the solution resistance (Rs), the charge transfer resistance (Rct), and the constant phase element (CCFE) define the nature of the electrochemical processes (fig. S6B). A factor “n” in equation (jωC = (jω)nCCPE) varies between a value of 1 and 0, with the higher extremity representing a pure capacitor while the lower characterizing a resistor. When n is between 0 and 1, its value provides information about diffusion phenomena, surface morphology, and other dissipative processes (25). After etching for 30 s, the value of n tends to decrease, likely due to increasing roughness and/or porosity on the surface of the electrode, as expected (26, 27) and as observed in SEM images (fig. S7). Although the initial electrode surface likely supports a thin oxide layer, electrochemical etching forms Mg(OH)2 according to Mg + 2H2O → Mg(OH)2 + H2. The combined effect of the oxide and hydroxide, which are both simultaneously forming and dissolving into the surrounding biofluids throughout the process (19, 28), leads to capacitive behavior between the electrolyte and electrode. As the etching proceeds, the thickness of the corrosion layer (d) increases, thereby decreasing the capacitance (C) according to C = εε0S · d−1 (where ε0, ε, and S are the vacuum permittivity, dielectric constant, and surface area of the electrode, respectively) (fig. S6) (29). After termination of electrochemical etching under applied bias, the residual Mg(OH)2 and oxides eventually disappear completely via dissolution at rates of several nanometers per day, depending on the details of the chemistry of the surrounding solution (19).

Fig. 2 Geometrically accelerated corrosion as the mechanism for opening a gate.

(A) Design of an implantable and wirelessly controlled, bioresorbable drug delivery system. (B) Illustration and image of a Mg gate defined by an opening through a cover of PBTPA. The locations where the edges of this opening meet the underlying Mg create regions of crevice corrosion. The insets show optical microscope (OM; left) and scanning electron microscope (SEM; right) images of the electrochemically accelerated corrosion that occurs along these edge locations. (C) Back side view images of an electrochemically etched Mg gate (3 mm by 3 mm) at an applied potential of 1 V (~5 mA) for 0, 30, 90, and 180 s, respectively. (D) Nyquist plot: Z′, real part of impedance; Z′′, imaginary part of impedance. (E) OM image of the electrochemically accelerated corrosion of a Mo gate (3 mm by 3 mm, 10 μm thick) at an applied voltage of 5 V (~6 mA) for 60 s. (F) Three-dimensional (3D) topography image and surface profile measurement of the corroded Mo gate near the edge of the PBTPA (1:1:2.5) opening, obtained using a 3D optical profiler (Nexview, Zygo Corporation, USA). Photo credit: Ji-Hyeon Park, Northwestern University.

Quantitative characterization of the crevice corrosion phenomena is most easily conducted with molybdenum (Mo) gates (10 μm thick), due to the comparatively smooth morphology of the thin oxide film (MoO3) and the reduced rates of dissolution compared to Mg. The central region, away from the perimeter, exhibits the slowest rates. A magnified OM image of the gate and an optical profilometry image at a vertex (Nexview, Zygo Corporation, USA) in Fig. 2 (E and F) confirm the differential rates of corrosion kinetics across different regions. The relative depth of the corrosion along the white arrow with the broken line (between A and B) in Fig. 2F indicates that the corrosion rates at the edges and vertex regions are ~10 times higher than that at the central region, i.e., ~5.6 × 10−8 and ~4.1 × 10−9 mg‧mm2‧s−1, respectively. These rates follow from estimates of the areas for uniform (~280 mm2) and crevice (~26 mm2) corrosion determined from the OM image (1 V for 200 s) and from the etched Mo volume extracted from the three-dimensional topology data (fig. S8A). These observations are consistent with crevice corrosion processes that arise at dissimilar junctions (16, 22, 23) due to reduced rates of mass transfer at the edges and associated enhancements in anodic effects. Figure S8B presents sequential images of the structure at 10, 20, and 30 s of electrochemical etching with a bias of 5 V. The images illustrate that the crevice corrosion at the perimeter of the anode dictates the opening of the gate and associated release. As a result, only a relatively small amount of the gate (i.e., along the perimeter) must be etched away to produce an opening event, thereby allowing for the rapid release of drugs upon a trigger event.

Trigger and release behaviors of bioresorbable drug delivery device

Figure 3 (A to D) summarizes the effect of applied voltage, gate area, and thickness on the time required to open the gate (t0), as determined using an electrochemical analyzer (Short VMP3, Bio-Logic Science Instruments, USA). Figure 3A shows the corrosion current as a function of time for gates with fixed dimensions (thickness, 30 μm; area, 3 mm2 by 3 mm2) at various applied voltages. The crevice corrosion leads to electrical isolation and opening, as defined by a sudden decrease in the corrosion current to a value close to zero (Fig. 3A). Analysis of these data defines the relationship between applied voltage, time (t0) required to open (fig. S9A), and corrosion rate (fig. S9B). Both the amount of etched metal and the corrosion rate follow Faraday’s law (eqs. S6 to S8 in note S3). As expected, t0 and the corrosion rate are proportional to the applied voltage. Figure 3B reveals a direct relationship between the gate area and t0 for a fixed voltage (0.5 V) and gate thickness (30 μm). Additional experiments involve studies of Mg gates with similar surface areas but different perimeters: circular (radius, r = 3 mm) and cross (length of a side, a = 2.38 mm) shapes (fig. S10A). The former (perimeter, 18.84 mm; area, 28.26 mm2) and latter (perimeter, 28.56 mm; area, 28.32 mm2) exhibit t0 values (n = 4, mean) of ~202 ± 65 and ~270 ± 41 s, respectively, as shown in fig. S10 (B and C). The 35% smaller perimeter of the circular shape compared to the cross leads to a ~35% shorter value for t0, indicating that the length of perimeter defines t0 rather than surface area, as expected due to the crevice corrosion mechanism. The gate thickness also influences t0, as the corrosion process must propagate through the thickness to induce an opening (Fig. 3C).

Fig. 3 Trigger and release behaviors of bioresorbable drug delivery vehicles with electrochemical control.

(A) Dependence of the trigger time on applied potential at fixed Mg gate size (30 μm thickness, 3 mm by 3 mm area). (B) Effect of the exposed area of the gate on trigger time at a fixed applied potential (0.5 V) and gate thickness (30 μm). (C) Dependence of trigger time on thickness of the gate, for a fixed applied potential (0.5 V) and gate area (3 mm by 3 mm). (D) Comparison of the trigger time of Mg (30 μm at 0.2, 0.5, and 1 V) and Mo (10 μm at 1 V) gates for various perimeters of the gates. (E) Kinetics of the release of doxorubicin after triggering to open an area of 2 mm by 2 mm in the Mg gates. (F) Leakage of drug (doxorubicin) through the layers of material used for the reservoir and the gates [black, Mg (50 μm thick); red, Mo (10 μm thick); and blue, PBTPA 1:4:7 (100 μm thick)] during immersion in PBS at body temperature (37°C). Photo credit: Jahyun Koo, Korea University.

The selection of gate material is also important. A comparison of t0 for Mo and Mg gates illustrates this point (Fig. 3D). The higher nobility of Mo compared to Mg reduces its corrosion rate, thereby increasing t0. Linear sweep voltammetry (LSV) offers a simple route to visualize and compare the corrosion properties of different metals. Figure S11 shows representative LSV polarization curves for Mg and Mo. The anodic dissolution of Mg begins ~−0.77 V, while Mo begins at ~−0.44 V (with respect to Ag/AgCl reference electrode). At any applied voltage, for otherwise similar conditions, the Mg corrodes at a higher rate than Mo, thereby reducing t0. On the basis of these results, devices with Mg gates are best suited for rapid drug release over short times, considering the relatively fast rates of natural dissolution of Mg in biofluids (~1 μm/day at 23°C) (19). Mo gates are applicable to systems that demand long-term dosing and survivability, considering the comparatively slow rates of dissolution (0.2 to 0.5 nm/day at 23°C) (19).

Demonstrations and studies of cumulative drug release rely on doxorubicin (0.2 mg diluted in 0.2 ml of PBS) in a wired device built using a reservoir constructed in PBTPA (1:4:7). Immersing such a device in 3 ml of PBS in a cuvette and electrochemically opening the gate enable time-dependent analysis of release via optical [UV-visible (UV-vis)] spectroscopic measurements of an absorption peak (λ = 485 nm) associated with the doxorubicin (30). Data collected in this manner define the kinetics of the diffusion-controlled release processes. Figure 3E shows the cumulative release of doxorubicin from a device with an Mg gate (2 mm by 2 mm, 30 μm thick) after applying a trigger at 1 V for 5 min. The increase in absorbance at 485 nm corresponds to gradual release of the drug into the surrounding PBS (fig. S12) (30). The data indicate that ~70% of the doxorubicin releases within 10 min after triggering. Figure 3F shows that the leakage of drugs from a completed system [black, Mg (50 μm thick); red, Mo (10 μm thick); blue, PBTPA 1:4:7 (100 μm thick)] before opening of the gate is negligible during immersion in PBS at body temperature (37°C) for more than 30 days (fig. S13).

As mentioned in the context of the results of Fig. 1F, processes of dissolution and bioresorption of the PBTPA reservoir determine the overall lifetime of the drug delivery platform. The functional lifetime (tf), as defined by the maximum time that the drugs can be stored in the system without leakage, depends on the rate of dissolution of the metal gate (i.e., Mg gate; ~30 days, 30 μm thick) in the absence of a triggering event. This time, then, can be written astf=h0k1where h0 is an initial thickness of gate, and k is its rate of dissolution in biofluids. The time required for the triggered release can therefore be expressed, for a given voltage, ast0=α(h0kt)Pm,(ttf)where α is a factor that depends on the corrosion chemistry and the voltage, t is the time of immersion in biofluid before the initiation of a trigger event, and Pm is the perimeter of gate. Here, t0 is linearly proportional to the thickness of the gate (h0kt) that remains at the time of triggering. For example, the functional lifetime of 30-μm Mg (tf,Mg) is about 30 days, considering the natural rate of Mg dissolution (kMg = ~1 μm/day) (19). In the case of Mo, the functional lifetime (tf,Mo) is ~103 times longer than Mg at the same thickness (19), while the trigger time of Mo (t0, Mo) is only ~10 times longer than Mg, according to Fig. 3D. The systems can be engineered over a wide range, to satisfy particular requirements.

In vitro cell demonstration of bioresorbable drug delivery device

Demonstrations of practical utility in oncology applications use a confluent culture of cells (NIH-3T3, HeLa, HepG2, and MDA-MB-231). Figure 4 (A to C) presents a series of optical and fluorescence images with phalloidin staining of cell F-actin (green color) and 4′,6-diamidino-2-phenylindole (DAPI) staining of the cell nucleus (blue color) before and after a trigger event. Figure 4A shows the initial cell configuration at the start of the test as a reference; the inset highlights the test platform. Figure 4B demonstrates the noncytotoxicity of a device that contains doxorubicin (0.2 mg; Sigma-Aldrich, USA) immersed in Dulbecco’s modified Eagle’s medium (DMEM) (10 ml; Sigma-Aldrich, USA) for 1 hour. Here, Fig. 4B(iii) shows DAPI-stained NIH-3T3 nuclei (blue color indicated by white arrows) and actin [green color in Fig. 4B(ii)], consistent with unhindered cell attachment and spreading, without any evidence of cytotoxicity. Figure 4C(iii) shows that the DAPI-stained NIH-3T3 nuclei significantly decrease upon RF triggered release of doxorubicin. The presence of DAPI staining outside of the nuclei and the decrease in the signals associated with DAPI-stained cells are both consistent with disruption and apoptosis induced by the doxorubicin (31), ~70% of which releases from the reservoir within 10 min of the gate-opening event (Fig. 3E). Figure 4D shows the relative number of alive NIH-3T3 cells determined by a cell counting kit-8 (CCK-8) as a function of time. During the initial stage (0 hours) and incubation (1 hour), the cell viability remains constant. Triggering at 1 hour after the start of the test results in a marked increase in the rate of cell death, as shown in Fig. 4D. Specifically, release of doxorubicin through the 3 mm by 3 mm gate decreases the cell population by half during a 1-hour period that includes 5 min of RF triggering, decreasing the area of cell adhesion (i.e., cell spreading) significantly. In addition, various tumor cells (HeLa, HepG2, and MDA-MB-231) provide similar results (Fig. 4, E to G). The viability of HeLa, HepG2, and MDA-MB-231 cells for 5 hours after triggering and release of doxorubicin are 16, 39, and 35%, respectively. The DAPI-stained tumor cells significantly decrease, consistent with an increased rate of death of tumor cells, with negligible prior changes in viability (Fig. 4, E to G, and fig. S14), as expected due to negligible rates of passive leakage of drugs.

Fig. 4 In vitro evaluation of NIH-3T3 cell and tumor cell (HeLa, HepG2, and MDA-MB-231) viability after triggered release of drug (doxorubicin).

(A to C) Series of optical and fluorescence images of NIH-3T3 cells with phalloidin staining of cell F-actin (green; ii) and DAPI staining of the nuclei (blue; iii) before and after triggered release. The inset shows an image of a test platform used to study cell viability. (A and B) Images of the initial cell configuration and after 1-hour incubation with a device immersed in Dulbecco’s modified Eagle’s medium (DMEM) before triggering, respectively. (C) Images after triggering and release of doxorubicin from the device. Relative viability of (D) NIH-3T3, (E) HeLa, (F) HepG2, and (G) MDA-MB-231 cells before and after triggering (release point, 1 hour). Data are means ± SD; n = 3 per group. Statistica software (Version 6.0) was used for statistical analysis followed by a t test. *P < 0.05 compared to any other group. Photo credit: Hojun Kim, University of Illinois at Urbana-Champaign.

In vivo operation of a multiple release, bioresorbable drug delivery device

Extension of this basic system to include multiple drug reservoirs and corresponding RF harvesters tuned to different resonance frequencies allows for timed triggering of multiple release events, on demand. This type of multiple reservoir system can be used with a single drug or multiple combinations of them. Figure 5A presents a schematic illustration of a device that includes three independently addressable reservoirs and three harvesters (same outer diameter, 12 mm; 16, 13, and 8 turns for the black, red, and blue coils, respectively; see fig. S15 for the detailed geometrical layout). Separate control follows from distinct operating/resonance frequencies for each harvester. In this example, the three coils use matching capacitors of 19, 23, and 85 pF, respectively, to achieve operating frequencies of 5.14, 9.92, and 14.78 MHz. The values of Q for these coils are 9, 15, and 15, with corresponding bandwidths of 0.6, 0.7, and 0.9 MHz, respectively (fig. S16). The different resonance frequencies, taken together with the physical separation of the coils, minimize mutual interference (detailed information is in note S1). RF power applied to a transmitting coil (diameter, 80 mm; 3 turns) placed on top of the system yields different voltages across each harvester. The induced voltage at the operating frequency of any one of the three harvesters is significantly larger (~10 times) than that of the other two (Fig. 5, B and C), as necessary for independent control and operation.

Fig. 5 In vivo operation of a wirelessly programmable, bioresorbable drug release vehicle with three separately addressable drug reservoirs for regulation of blood glucose.

(A) Illustration of a system with three separate reservoirs and wireless stimulator units. (B) Simulated and (C) experimentally measured (data are means ± SD; n = 3 per group) voltages of the three separate harvesters at different operating frequencies, to demonstrate minimal cross-talk. (D and E) Images of a device and surgical procedures for implantation in the subdermal area of the back of a rat model. (F) Changes in blood glucose level induced by wirelessly triggering the release of insulin sequentially from the three reservoirs. RF with different frequencies (5, 10, and 15 MHz) triggered each reservoir. After each release event and a subsequent hour of monitoring, glucose was injected under the skin to return the glucose level to its initial value within 30 min. Photo credit: Jahyun Koo, Korea University.

Figure 5D shows an optical image of such a device, including three independent reservoirs and three harvesters. In vivo demonstrations involve systems of this type filled with insulin and implanted under the skin of male Lewis rats (Fig. 5E). RF power delivered at different frequencies (5, 10, and 15 MHz) and different times independently triggers each reservoir. For each case, more than 80% of the insulin releases into the surroundings within 10 to 30 min for gates with sizes of 3 mm by 3 mm, as shown in fig. S17. The insulin causes the liver to increase the conversion of glucose into glycogen and thereby reduce the glucose levels in the blood (32). A commercial meter (GLUCOCARD Vital, Arkray Inc., Minneapolis, USA) yields information on blood glucose concentration after the insulin release events (insulin solution human, Sigma-Aldrich, USA; 0.9 IU, defined as the “biological equivalent” of 34.7 μg of pure crystalline insulin per 1 IU). Triggered release of insulin from the implanted system has the expected effect. Triggering the first reservoir using an RF frequency of 5 MHz leads to the release of the first amount of insulin (0.9 IU diluted in 0.2 ml of PBS), as shown in Fig. 5F. An hour after releasing insulin and monitoring the glucose level, injection of glucose solution (3 ml; 50% dextrose injection, USP, Hospira Inc., USA) under the skin (subcutaneous tissue of the back of the animal) returns the glucose level to its initial value (over 90 mg/dl) within 30 min. After a 30-min recovery period, triggering the second reservoir (using RF at 10 MHz) releases another dose of insulin (0.9 IU diluted in 0.2 ml of PBS). Another hour after monitoring, injection of glucose returns the level to its initial value again. Triggering the third reservoir (using RF at 15 MHz) repeats the process, thereby demonstrating the reliable operation of this type of wirelessly programmed and multiple drug release platform. This implantable system might be valuable for long-term usages with multiple days’ release of insulin when patients cannot perform injections themselves and they do not have access to health professionals.

In another example, integration of polymer structures near and around the gates allows for directional and localized release of lidocaine for local pain block on the sciatic nerve. Figure 6A illustrates the three independent reservoirs of this platform and its nerve cuff for localized pharmacological delivery to the site of interest. The inset of Fig. 6A highlights the interface between the triple reservoirs and the poly(lactic-co-glycolic acid) (PLGA) cuff (4 mm by 8 mm, ~20 μm thick) that wraps the sciatic nerve to localize the release. A schematic illustration and image of the device and associated surgical procedures for implantation near the right sciatic nerve of a male Lewis rat appear in Fig. 6 (B to D). RF power delivered at different frequencies (5, 10, and 15 MHz) and different times independently triggers each reservoir. For each case, more than 80% of the lidocaine releases along the PLGA cuff within 30 min for gates with sizes of 2 mm by 2 mm, as shown in Fig. 3E. The lidocaine preferentially binds to the inactivated state of the voltage-gated sodium channels that conduct electrical impulses and mediate fast depolarization along nerves to eliminate pain (33, 34). Maximum electromyograms (EMGs) obtained from the tibialis anterior (TA) muscle in uninjured rats confirm the ability to block the sensitivity of the sciatic nerve by programmed release of lidocaine (0.2%, ~20 μl), as shown in Fig. 6E. The maximum EMG drops rapidly after RF triggering and release. Figure 6F presents representative EMG data collected in intervals of 15 min after triggered release events (0.2%, ~20 μl) in series (black, baseline; red, after the first trigger; blue, after the second trigger; and purple, after the third trigger). The muscle responses decrease after each release. In this manner, bioresorbable, localized release platforms of this type may offer potential utility in programmed, on-demand pain relief during and after recovery from an injury or a surgical operation.

Fig. 6 In vivo demonstration of a wirelessly programmable, bioresorbable drug release vehicle with three independent reservoirs and a cuff structure as a local anesthetic for mitigation of pain.

(A) Illustration of a system with triple reservoirs and a cuff structure as an interface to the sciatic nerve of a rat model. The inset highlights the design details and the nerve interface. (B and C) Schematic illustration and image of the device. (D) Images at various stages of implantation of the device and integration of its flexible poly(lactic-co-glycolic acid) (PLGA) cuff (4 mm by 8 mm, ~20 μm thick) with the sciatic nerve to hold the position of the reservoir and to localize the release to the nerve. (E) Changes in the maximum EMG signal associated with wirelessly triggered released of lidocaine from each of the three reservoirs in series. Here, RF with different frequencies (5, 10, and 15 MHz) triggered each reservoir. After each release event of lidocaine (0.2%, ~20 μl), the maximum EMG was recorded from the tibialis anterior (TA) muscle (data are means ± SD; n = 2). (F) Representative electromyogram (EMG) data for every 15 min after the trigger events and corresponding release of lidocaine (0.2%, ~20 μl) in series (black, baseline; red, 15 min after the first trigger; blue, 15 min after the second trigger; and purple, 15 min after the third trigger). Photo credit: Jahyun Koo, Korea University.

The materials and strategies for fabrication support wide-ranging choices in sizes and geometries for the devices, including the use of miniaturized reservoirs for small-animal model studies. Figure S18A illustrates in vivo operation of a device with a single reservoir (5 mm by 5 mm by 2 mm) and a nerve cuff (2 mm by 8 mm, ~20 μm thick) for localized, pharmacological delivery to the sciatic nerve of a mouse. Here, the reservoir can be designed with dimensions across a wide range, down to a few hundred microns, to align with the minimum effective dose levels (i.e., micro- to milliliter). Figure S18B shows the procedures for implantation of a platform with a flexible PLGA (2 mm by 8 mm, ~20 μm thick) nerve cuff that wraps sciatic nerve to hold the position of the reservoir and guide the release direction of lidocaine (1%, ~20 μl) by RF triggering with 5 MHz for 5 min. Figure S18C shows an optical image of the sciatic nerve and adjacent muscle tissue for the case of the release of a blue dye solution. After the release of lidocaine (1%, ~20 μl), the compound muscle action potential (CMAP; black) and sensory nerve action potential (SNAP; red) show expected changes over 2 hours (data are means ± SD; n = 3), as shown in fig. S18D. Complete blockage of activity of sciatic nerve occurs within 15 min after release and activity gradually recovers over the next ~2 hours, as illustrated (fig. S18E) by the decrease in CMAP (left) and SNAP (right) signals (red) relative to those before the trigger event (black). Specifically, the lidocaine blocks ~90% of CMAP and ~94% of SNAP during the initial period after release. This miniaturized system can also support multiple reservoirs with different types of drugs for cocktail therapy in oncology applications and/or long-term release of drug for chronic treatment.

In vivo biocompatibility studies of bioresorbable device

Although the experiments described above reveal no signs of inflammation or immune reactions, separate evaluations of biocompatibility are useful. Tests for this purpose involve subdermal implantation of Mg (group I) and Mo (group II) devices, each of which includes an encapsulation layer of PBTPA (1:4:7, ~100 μm thick), a gate (3 mm by 3 mm) and counter electrode (Mg, 50 μm thick; Mo, 10 μm thick), and a PBTPA (1:4:7) reservoir (1 mm by 1 cm, ~900 μm thick), in three groups of animals. A block of high-density polyethylene (HDPE; U.S. Food and Drug Administration–approved nontoxic material), with 1-mm thickness and 1 cm by 1 cm lateral dimensions similar to those of the test devices, serves as a control (group III). Here, electrochemical triggering uses a wired connection at 1 V for 5 min, performed shortly after subdermal implantation. The devices remain implanted for 5 weeks after removal of the wired connection. Hematoxylin and eosin images of stained tissue sections collected after this period appear in Fig. 7 (A and B) and figs. S19 and S20. The metal components undergo dissolution and bioresorption within this time. Some minimal inflammatory response and fibrosis appear in close proximity to the implants, but no significant evidence of injury or damage occurs at the adjacent tissue and muscle layers. Additional evaluations involve careful examination of each hematoxylin and eosin slide for the presence of acute and chronic inflammation, granulation tissue formation, and fibrosis. OM images [high-power field (HPF; 40× objective] at the highest density of inflammation yield counts of neutrophils, lymphocytes, and giant cells (Fig. 7C). Presence or absence of granulation tissue can be scored as absent, focal, or diffuse. Fibrosis scores on the Masson stain use were as follows: none = 0, mild = 1, moderate = 2, and severe = 3, as in Fig. 7. Measurements of weight change at 5 weeks after implantation show no significant differences (fig. S21). Counts of white blood cells in peripheral blood serum by cytometric bead arrays also indicate no significant differences between groups (fig. S22). These results, together with previously reported findings, provide strong evidence of the biocompatibility of the individual constituent materials used in the platforms presented here, such as PLGA (35), Mg (36), Mo (37), Si NM (20) and their use in other types of devices (14).

Fig. 7 In vivo biocompatibility studies.

Hematoxylin and eosin images of stained tissue sections at 5 weeks after implantation of (A) devices and (B) samples of HDPE. Middle and right images show adjacent muscle fascia and muscle tissue, respectively. (C) Evaluations of histological scoring for reference controls (HDPE) and test groups (Mg metal gate and Mo metal gate devices) (n = 3 per group). PMN, polymorphonuclear. Boxplots show the median (center line), the third and first quartiles (upper and lower edge of box, respectively), and the largest and smallest value that is ≤1.5 times the interquartile range (limits of upper and lower whiskers, respectively). Photo credit: Matthew MacEwan, Washington University in St. Louis.

In summary, wirelessly programmable, battery-free drug delivery systems constructed entirely of bioresorbable materials represent a versatile class of technology for targeted pharmacologic treatment across a range of applications. The efficient containment and the engineered reservoir approach facilitate application to broad classes of pharmaceuticals, including proteins and hormones. Additional opportunities are in cocktail therapies and controlled pharmacokinetics enabled by multiple, independently controlled reservoirs. The development of advanced approaches based on chip-based microcontrollers to scale the number of reservoirs significantly beyond those of the systems presented here represents a direction for future work. These schemes enable long-term delivery and precise dosing if implemented with reservoirs that have individual volumes below a therapeutic concentration.


Preparation of wireless, bioresorbable drug release vehicles

Preparation of the materials began with mixing of 4-PA, TTT, and 1,4-butanedithiol with a molar ratio of 1:4:7 (PBTPA 1:4:7) or 1:1:2.5 (PBTPA 1:1:2.5) in polydimethylsiloxane (PDMS) molds. Initiating a thiol-ene click reaction by adding photoinitiator (5 weight %) and exposing to UV light (λ = 365 nm) formed PBTPA for the bioresorbable reservoirs (13). Wet etching of foils (Mg foil, 10 to 50 μm thick; or Mo foil, 10 μm thick) yielded bioresorbable metal electrodes. An uncured layer of PBTPA bonded a film of PBTPA (50 μm thick) with holes defined by a laser cutting process onto the metal electrodes. Exposure to UV light (4 W, λ = 365 nm) for 10 min completely cured the entire structure. The extended metal electrodes were connected to a wireless stimulator unit built using a RF receiver coil of Mg, an RF diode constructed using a Si NM, and a parallel-plate capacitor in a multilayer stack of Mg/SiO2/Mg. Biodegradable conductive paste (Candelilla wax/W powder) electrically connected the individual components (14).

Measurements of permeability of drugs through constituent materials

A 1-cm-thick slab of PDMS (Sylgard 184, Dow Corning, USA) cast in a well structure served as a test vehicle for assessing permeation of aqueous solutions of drugs through layers of materials used in the devices (fig. S11). Mg (50 μm thick), Mo (10 μm thick), or PBTPA (1:4:7, 100 μm) served as seals on the top of the PDMS well, bonded using an epoxy (LOCTITE EPOXY, Henkel Corp., USA). A syringe injection process delivered a drug solution (1 ml) through the side wall of the well. Sealing this injection location with epoxy prevented leakage. A coating of epoxy covered the entire system, including the side and back wall surfaces of the PDMS, to securely bond the test film in a vial filled with PBS (10 ml) and held at body temperature (37°C) for 30 days. At regular time intervals, samples of PBS (3 ml) collected from the vial were transferred to a cuvette for UV-vis spectroscopy. An absorption peak at 485 nm in the UV-vis spectrograms (UV-2450, Shimadzu Corp., Japan) allowed determination of the concentration of doxorubicin, as described previously (30). After each measurement, the PBS was returned to the original vial.

In vitro demonstration and evaluation of cell (NIH-3T3, MDA-MB-231, HepG2, and HeLa) viability

NIH-3T3 fibroblasts were cultured in DMEM (Gibco-BRL, USA) supplemented with 10% (v/v) fetal bovine serum (Gibco-BRL) and penicillin-streptomycin (100 U/ml; Gibco-BRL). The relative numbers of live cells were determined using a CCK-8 according to the manufacturer’s protocol (n = 3 per group). MDA-MB-231, NIH-3T3, and HepG2 cells treated with the device, electrical trigger, and/or doxorubicin were imaged using an OM. The cells were fixed, permeabilized, and subsequently incubated with Alexa Fluor 488–phalloidin (Molecular Probes) and DAPI (Sigma-Aldrich) to stain cell actin and nucleus, respectively. Imaging used a laser scanning confocal microscope (LSM 710, Zeiss). Phalloidin staining of cell actins enabled examination of the effects on cell adhesion.

EIS measurements of corrosion processes

Gates of Mg and Mo with circular shapes (radii of 1, 1.2, 1.4, 1.6, and 1.8 mm) defined by PBTPA (1:4:7) were submerged in an electrochemical cell at room temperature with PBS as the electrolyte and with a counter electrode of Cu and a reference electrode of Ag/AgCl. The corrosion followed from application of potentials at 0.5 to 5 V for 0.5 to 5 min using a potentiostat (Metrohm Autolab B.V., The Netherlands). The polarization measurements involved a scan rate of 1 mV/s and a scanning range from −1 to 1 V.

Electromagnetic simulation

Finite-element analysis yielded the scattering parameters (S11), the inductance (L), and the Q factor (Q) of the Mg RF coil with a matching capacitor. The simulations (Ansys HFSS 13 User’s Guide, Ansys Inc., 2011) used a lumped port to define the S11 and the port impendence (Z). An adaptive mesh (tetrahedron elements) ensured computational accuracy, to yield L = ZIm/(2πf) and Q = |ZIm/ZRe|, where ZRe, ZIm, and f represent the real and imaginary parts of Z and the frequency, respectively. A transmission coil (80 mm diameter, 3 turns, and winding with 1.6-mm diameter copper wire) added to the simulation model yielded a relationship between the power transfer efficiency and operating voltage.

In vivo demonstration of wirelessly triggered lidocaine release for sciatic nerve block

Male mice (30 g; C57BL/6J, the Jackson laboratory, USA) were anesthetized using isoflurane gas (3% for induction and 2% for maintenance) during surgical implantation of a bioresorbable drug delivery reservoir onto the right sciatic nerve of the animal. After the implantation, the surgical wound was closed with 8-0 Vicryl sutures and Autoclip wound clips (12020-09, Fine Science Tools). A signal generator (3390, Keithley, USA) and a high-frequency amplifier (8447E, Agilent, USA) provided RF power to a transmitter coil (80 mm diameter, 3 turns) placed over the implantation site to wirelessly power the implanted drug delivery device. After triggering the Mg metal gate for 5 min and release of lidocaine (Xylocaine-MPF 1%, Fresenius USA), CMAP (black) and SNAP (red) were measured (data are means ± SD; n = 3) with 1″ length, 0.30-mm diameter concentric needle electrodes (S53153 TECA, USA) on a VikingQuest EMG system using Synergy master software (982A0386, Natus, USA).

In vitro insulin release

Here, devices with insulin solution (0.9 IU diluted in 0.2 ml of PBS) and various metal gate sizes (1 mm by 1 mm to 5 mm by 5 mm) were triggered in a 25-ml vial filled with 10 ml of PBS solution. Small volumes (3 ml) of solution collected from different devices and vials for each time point were transferred in an insulating box (~2°C, within 24 hours) to the Diabetes Research Center at Washington University in St. Louis for measurements of the concentration of insulin.

In vivo demonstration of wirelessly triggered insulin release from systems with multiple reservoirs

Male Lewis rats (300 g; Charles River Laboratories) were anesthetized using isoflurane gas (4% for induction and 2% for maintenance) during surgical implantation of a bioresorbable drug delivery reservoir into a subcutaneous pocket in the back area of the animal. After implantation, the surgical wound was closed with 4-0 nylon sutures. A signal generator (3390, Keithley, USA) and a high-frequency amplifier (8447E, Agilent, USA) provided RF power to a transmitter coil (80 mm diameter, 3 turns) placed over the implantation site to wirelessly power the implanted drug delivery device. After triggering the metal gate, blood glucose level monitoring was performed each hour over a time of 5 hours. A 23-gauge needle was used to prick the tip of the toe for blood sampling.

In vivo biocompatibility tests

Two types of devices [Mg gate device (group I, n = 3) and Mo gate device (group II, n = 3)] and a control group (group III, n = 3) were implanted in male Lewis rats (n = 9). All animal studies were performed in accordance with Institutional Animal Care and Use Committee at the Washington University in St. Louis. Male Lewis rats (300 g; Charles River Laboratories) were anesthetized using 4% isoflurane/96% oxygen (induction) and 2% isoflurane/98% oxygen (maintenance) administered by inhalation. Before implantation, test devices (Mg gate and Mo gate) and reference materials (HDPE) were sterilized by exposure to ethylene oxide. The devices were implanted into a pocket created beneath the skin on the backs of the animals. Electrical triggering involved a wired connection at 1 V for 5 min to open the gates. After the triggering event, the device was implanted for 5 weeks with the wired connection removed. At the terminal time point, the animals were weighed (fig. S21), and venous blood was collected from the tail vein to assess for complete blood count and systemic toxicity (fig. S22). For histological analysis, the skin tissue and subcutaneous pockets containing the materials were excised and fixed in 10% neutral-buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin.

Hematoxylin and eosin staining

Fixed skin samples were placed in a Tissue-Tek VIP 1000 tissue processor where they were submerged in graded alcohols followed by xylene and infiltration with paraffin. An embedding process formed paraffin blocks that were then sectioned on a Leica RM2125 RTS rotary microtome. The slides were deparaffinized and hydrated through graded alcohols. Staining used exposure to a modified Harris hematoxylin (Richard-Allen Scientific, Kalamazoo, Michigan) for 2 min followed by differentiation in 0.1% acid alcohol and bluing in 0.1% ammonia water. After two rinses in 95% ethyl alcohol, samples were placed in an eosin Y with phloxine (Richard-Allen Scientific, Kalamazoo, Michigan) for 30 s. The samples were then dehydrated, cleared, and mounted.

Toluidine blue staining

The slides were deparaffinized and hydrated through graded alcohols to water. The slides were then placed in 0.1% aqueous toluidine blue O (Allied Chemical, Rochester, NY) solution for 10 min. After rinsing in tap water, the samples were dehydrated quickly through 95 and 100% ethyl alcohol. This step was closely monitored to yield the correct amount of differentiation. The slides were then cleaned in xylene and mounted.

Histological scoring

A pathologist (M.P.) performed the histologic evaluation of the tissue at the Northwestern University, Feinberg School of Medicine. Each hematoxylin and eosin slide was carefully reviewed for the presence of acute and chronic inflammation, granulation tissue formation, and fibrosis. Neutrophils, lymphocytes, and giant cells were counted in a representative HPF (40× objective) with the highest density of inflammation. Presence or absence of granulation tissue was scored as absent, focal, or diffuse. Fibrosis was scored on a Masson stain as none = 0, mild = 1, moderate = 2, and severe = 3.


Supplementary material for this article is available at

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.


Acknowledgments: The authors specially thank J. Park for the help in analysis of cell test and imaging. Funding: J.Ko. acknowledges the support from the National Research Foundation of Korea (NRF-2020R1F1A1068083). Z.X. acknowledges the support from the Fundamental Research Funds for the Central Universities [grant no. DUT20RC(3)032]. X.F. acknowledges the support from the National Basic Research Program of China (grant no. 2015CB351900) and the National Natural Science Foundation of China (grant no. 11320101001). H.K and C.L. are partially supported by the NIH under grant no. 1DP2EB024377-01. Y.S.O and I.P are supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (no. 2018R1A2B200491013). H.M.L is supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2017R1E1A1A03071049). Y.H. acknowledges the support from NSF (grant no. 1635443). S.-K.K is supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2019R1C1C1004232). J.A.R. acknowledges support from the Center for Bio-Integrated Electronics at Northwestern University. Author contributions: J.Ko., S.-K.K., M.M., and J.A.R. designed the research. J.Ko., Y.S.C., S.B.K., Z.X., J.Kh., Y.Y., H.K., M.K.P., K.D., G.L., D.D., Y.-Y.C., S.M.L., K.Li., S.J., H.W., J.-H.K., W.J.J., and J.-H.P. conducted in vitro and in vivo experiments. Z.X., K.Li., H.W., X.F., and Y.H. conducted the structural designs and electromagnetic modeling. J.Ko., Y.S.C., S.B.K., H.K., A.J.B., Z.X., K.J., K.Le.., J.Ki., S.-G.C., G.L., Y.S.O., I.P., S.S.K., X.F., C.-H.L., A.B., C.L., D.H., H.M.L., Y.H., C.K.F., W.Z.R., M.M., S.-K.K., and J.A.R. discussed and interpreted the data. J.Ko., Y.S.C., S.B.K., A.J.B., M.M., S.-K.K., and J.A.R. wrote the manuscript, and all authors revised it. D.D. conducted animal surgery to demonstrate drug release in mouse model. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Stay Connected to Science Advances

Navigate This Article